KEAP1 and Parkinson disease: Compounds 28a and 28b (Figure 12) inhibit the KEAP1–NRF2 interaction with moderate inhibitory potency and induce the expression of NRF2 downstream target genes, leading to neuroprotection in an in vitro model of PD [161].